PT - JOURNAL ARTICLE AU - Files, D. Clark AU - Matthay, Michael A. AU - Calfee, Carolyn S. AU - Aggarwal, Neil AU - Asare, Adam L. AU - Beitler, Jeremy R. AU - Berger, Paul A. AU - Burnham, Ellen L. AU - Cimino, George AU - Coleman, Melissa H. AU - Crippa, Alessio AU - Discacciati, Andrea AU - Gandotra, Sheetal AU - Gibbs, Kevin W. AU - Henderson, Paul T. AU - Ittner, Caroline A.G. AU - Jauregui, Alejandra AU - Khan, Kashif T. AU - Koff, Jonathan L. AU - Lang, Julie AU - LaRose, Mary AU - Levitt, Joe AU - Lu, Ruixiao AU - McKeehan, Jeffrey D. AU - Meyer, Nuala J. AU - Russell, Derek W. AU - Thomas, Karl W. AU - Eklund, Martin AU - Esserman, Laura J. AU - Liu, Kathleen D. AU - , TI - The I-SPY COVID Adaptive Platform Trial for COVID-19 Acute Respiratory Failure: Rationale, Design and Operations AID - 10.1101/2022.05.05.22274628 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.05.22274628 4099 - http://medrxiv.org/content/early/2022/05/07/2022.05.05.22274628.short 4100 - http://medrxiv.org/content/early/2022/05/07/2022.05.05.22274628.full AB - Introduction The COVID-19 pandemic brought an urgent need to discover novel effective therapeutics for patients hospitalized with severe COVID-19. The ISPY COVID trial was designed and implemented in early 2020 to evaluate investigational agents rapidly and simultaneously on a phase 2 adaptive platform. This manuscript outlines the design, rationale, implementation, and challenges of the ISPY COVID trial during the first phase of trial activity from April 2020 until December 2021.Methods and analysis The ISPY COVID Trial is a multi-center open label phase 2 platform trial in the United States designed to evaluate therapeutics that may have a large effect on improving outcomes from severe COVID-19. The ISPY COVID Trial network includes academic and community hospitals with significant geographic diversity across the country. Enrolled patients are randomized to receive one of up to four investigational agents or a control and are evaluated for a family of two primary outcomes—time to recovery and mortality. The statistical design uses a Bayesian model with “stopping” and “graduation” criteria designed to efficiently discard ineffective therapies and graduate promising agents for definitive efficacy trials. Each investigational agent arm enrolls to a maximum of 125 patients per arm and is compared to concurrent controls. As of December 2021, 11 investigational agent arms had been activated, and 8 arms were complete. Enrollment and adaptation of the trial design is ongoing.Ethics and dissemination ISPY COVID operates under a central institutional review board via Wake Forest School of Medicine IRB00066805. Data generated from this trial will be reported in peer reviewed medical journals.Trial registration number Clinicaltrials.gov registration number NCT04488081Strengths and limitations of this studyThe ISPY COVID Trial was developed in early 2020 to rapidly and simultaneously evaluate therapeutics for severe COVID-19 on an adaptive open label phase 2 platformThe ISPY COVID Adaptive Platform Trial Network is an academic-industry partnership that includes academic and community hospitals spanning a wide geographic area across the United StatesOf December 2021, 11 investigational agent arms have been activated on the ISPY COVID Trial PlatformThe ISPY COVID Trial was designed to identify therapeutic agents with a large clinical effect for further testing in definitive efficacy trials—limitations to this approach include the risk of a type 2 errorCompeting Interest StatementDCF has received funding from Quantum Leap Healthcare Collaborative related to this work and from the National Institutes of Health unrelated to this work. DCF has worked as a consultant for Cytovale and Medpace unrelated to this work. ICJME forms from all authors will be uploaded.Clinical TrialNCT04488081Funding StatementEffort was sponsored by Allergan, Amgen, Takeda Pharmaceutical Company, Implicit Bioscience, J&J, Pfizer, Roche/Genentech, Apotex, Omeros, the COVID-19 Research and Development Consortium, a FAST Grant from Emergent Venture George Mason University, the DoD Defense Threat Reduction Agency (DTRA), The Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) and the Grove Foundation. Effort was sponsored in part by the U.S. Government under Other Transaction number W15QKN-16-9-1002 between the MCDC and the Government. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ISPY COVID operates under a central institutional review board via Wake Forest School of Medicine IRB00066805. Data generated from this trial will be reported in peer reviewed medical journals.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe trial procedures and protocols are regulated under a central IRB structure at the Wake Forest School of Medicine. All patients (or designated surrogate) entering the portion of the trial that receive an investigational agent undergo patient level consent by study staff and/or study investigators. Protocol revisions are announced at weekly investigator and coordinator meetings and are submitted to the FDA and IRB. No patient level data will be released, and all personal information will remain confidential and de-identified. Results of the agents completing the ISPY COVID Trial will be reported in press releases, scientific abstracts and manuscripts.